Jennifer B. Dwyer, MD, PhD

a:2:{i:0;s:61:"Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut";i:1;s:169:"

JCP
BI 1358894 in Borderline Personality Disorder
Original Research

January 13, 2025

Although the primary endpoint was not met, BI 1358894 was well-tolerated with no increase in self-harm or suicidality.
, , , et al

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe